PRESS-RELEASE ·Filed Jul 26, 2026
Press release · Leadership
Actionable Insight • Neutral
This filing is a routine PR announcement with no trading implications. Monitor upcoming regulatory catalysts for olverembatinib and lisaftoclax global Phase III trials for material events.
Final — all horizons settled through T+60d
AAPG ▼ -18.69% at T+60d
NEUTRAL call -18.69% · α vs SPY -22.39% · entry $18.89 → $15.36
T+1d
-3.20%
call -3.20% · α -3.44%
$18.29
settled 3mo ago
T+5d
-7.76%
call -7.76% · α -8.83%
$17.43
settled 3mo ago
T+20d
-11.54%
call -11.54% · α -14.84%
$16.71
settled 2mo ago
T+60d
-18.69%
call -18.69% · α -22.39%
$15.36
settled 8d ago
Price Chart
Loading chart...
Executive Summary
Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, was ranked No. 3 in The Medicine Maker Power List 2026 Small Molecules category. This is a personal industry recognition with no financial or operational impact on the company.
Key Facts
- Dr. Dajun Yang ranked No. 3 in The Medicine Maker Power List 2026 Small Molecules category
- Recognition highlights his leadership in advancing olverembatinib and lisaftoclax
- No financial data, guidance, or material business developments disclosed
Financial Impact
None — this is a non-financial recognition event
Risk Factors
- No new risks disclosed
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3333236 |
29 reports for AAPG
67% Hit rate @ T+1 Went positive at some point 5 of 6 best @ T+20▲ +13.03%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.67 (−4.99%) |
Oct 21, 2026 5d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.67 (−1.68%) |
Oct 15, 2026 12d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.67 (−0.14%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.67 (+4.55%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $14.67 (+15.30%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.67 (−12.96%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.67 (−12.70%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.67 (−22.34%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.67 (−20.14%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $14.67 (−23.75%) |
Showing 10 of 29
US Market Status
Market Open — Closes in 5h 10m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers